Trendepvantage2017-09-21 12:24Read 0
In the controversy over the abbreviated presentation of results from Checkmate-214 at an Esmo press conference there has been little chance to examine the questions posed by the kidney cancer study’s surprising results.
Healthecancer2017-09-21 12:24Read 0
Scientists at the Virginia Tech Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time.
EVENTSfiercebiotech2017-09-21 10:56Read 0
Chinese neurological disorders startup XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.
R&Dfiercebiotech2017-09-21 10:56Read 0
Glythera has struck a deal to access a source of antibodies against specified targets. Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned antibody drug conjugates (ADCs).
Healthecancer2017-09-20 13:36Read 0
scientists at Rutgers University-New Brunswick have now found that getting rid of the enzyme entirely can increase the risk of cancer, inflammation and other ills.
Trendpmlive2017-09-20 13:36Read 0
Teva has announced two deals in quick succession to sell off the entirety of its women's health business assets, raising almost $2.5bn that will go towards paying off its debts.
R&Dclinicaltrials2017-09-20 13:36Read 1
Roche has reported that its cancer drug Venclexta/Venclyxto (venetoclax), developed jointly with AbbVie, has succeeded in a phase 3 study in chronic lymphocytic leukaemia (CLL) patients by meeting its primary endpoint.
Trendfiercebiotech2017-09-20 13:36Read 1
The FDA cleared Medtronic's latest spinal cord stimulation system for the treatment of chronic intractable pain. The world's smallest SCS, the Intellis device offers activity tracking and personalized pain relief.
Trendpmlive2017-09-19 13:37Read 1
Swiss biotech Tesaro has picked up a CHMP recommendation for its PARP inhibitor Zejula as a maintenance therapy for ovarian cancer, upping the ante in its rivalry with AstraZeneca and Clovis Oncology.
EVENTSfiercebiotech2017-09-19 13:37Read 0
The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to spur research into the use of T cell receptor (TCR)-based therapeutics to treat tuberculosis and HIV.